Literature DB >> 34308748

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.

Daniel Re1,2, Jérôme Barrière3, Emmanuel Chamorey4, Margaux Delforge5, Lauris Gastaud2, Emmanuel Petit3, Axel Chaminade3, Benjamin Verrière5, Frédéric Peyrade2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34308748     DOI： 10.1080/10428194.2021.1957877

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  20 in total

Review 1.  Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose.

Authors:  Andrew N Margioris
Journal:  Hormones (Athens)       Date:  2022-06-24       Impact factor: 3.419

Review 2.  A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.

Authors:  Maryam Noori; Shadi Azizi; Farhan Abbasi Varaki; Seyed Aria Nejadghaderi; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2022-07-12       Impact factor: 5.714

Review 3.  Vaccination for SARS-CoV-2 in Hematological Patients.

Authors:  Niccolò Riccardi; Marco Falcone; Dafna Yahav
Journal:  Acta Haematol       Date:  2022-02-25       Impact factor: 3.068

4.  Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.

Authors:  Joanne S K Teh; Julien Coussement; Zoe C F Neoh; Tim Spelman; Smaro Lazarakis; Monica A Slavin; Benjamin W Teh
Journal:  Blood Adv       Date:  2022-04-12

Review 5.  Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.

Authors:  C Corti; G Antonarelli; F Scotté; J P Spano; J Barrière; J M Michot; F André; G Curigliano
Journal:  Ann Oncol       Date:  2021-10-28       Impact factor: 32.976

6.  Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma.

Authors:  Lindsey Wang; Nathan A Berger; Rong Xu
Journal:  JAMA Netw Open       Date:  2021-11-01

7.  Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.

Authors:  Deniz C Guven; Taha K Sahin; Saadettin Kilickap; Fatih M Uckun
Journal:  Front Oncol       Date:  2021-11-04       Impact factor: 6.244

8.  A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.

Authors:  Carlo Visco; Luigi Marcheselli; Roberto Mina; Marianna Sassone; Anna Guidetti; Domenico Penna; Chiara Cattaneo; Valentina Bonuomo; Alessandro Busca; Andrés José María Ferreri; Riccardo Bruna; Luigi Petrucci; Roberto Cairoli; Marco Salvini; Lorenza Bertù; Marco Ladetto; Sofia Pilerci; Antonello Pinto; Safaa Ramadan; Francesco Marchesi; Michele Cavo; Luca Arcaini; Elisa Coviello; Alessandra Romano; Pellegrino Musto; Massimo Massaia; Nicola Fracchiolla; Monia Marchetti; Annamaria Scattolin; Maria Chiara Tisi; Antonio Cuneo; Matteo Della Porta; Livio Trentin; Marco Turrini; Filippo Gherlinzoni; Agostino Tafuri; Sara Galimberti; Monica Bocchia; Valeria Cardinali; Daniela Cilloni; Alessandro Corso; Daniele Armiento; Luigi Rigacci; Elettra Ortu La Barbera; Carlo Gambacorti-Passerini; Giuseppe Visani; Daniele Vallisa; Adriano Venditti; Carmine Selleri; Annarita Conconi; Patrizia Tosi; Francesco Lanza; Anna Candoni; Mauro Krampera; Paolo Corradini; Francesco Passamonti; Francesco Merli
Journal:  Blood Adv       Date:  2022-01-11

9.  Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.

Authors:  Andrea Becerril-Gaitan; Bryan F Vaca-Cartagena; Ana S Ferrigno; Fernanda Mesa-Chavez; Tonatiuh Barrientos-Gutiérrez; Marco Tagliamento; Matteo Lambertini; Cynthia Villarreal-Garza
Journal:  Eur J Cancer       Date:  2021-10-26       Impact factor: 9.162

Review 10.  Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.

Authors:  Jérôme Barrière; Michel Carles; Clarisse Audigier-Valette; Daniel Re; Zoubir Adjtoutah; Barbara Seitz-Polski; Valérie Gounant; Diane Descamps; Gérard Zalcman
Journal:  Eur J Cancer       Date:  2021-12-16       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.